Navigation Links
CRi Announces Maestro 2, the Next Generation in Vivo Optical Imaging Systems

WOBURN, Mass., Nov. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the launch of Maestro 2 optical imaging systems in North America. The Maestro 2 received widespread acclaim at the both the recent Society of Molecular Imaging/Academy of Molecular Imaging joint conference for in vivo imaging, and at the Stanford University Small Animal Imaging Workshop as well. Maestro 2, the fully automated version of the award-winning Maestro small animal imaging system, is the ideal optical imaging system for both core imaging facilities and individual laboratories using fluorescence-based imaging methodologies.

Maestro 2 combines the sensitivity and features of the original Maestro in vivo imaging system with advanced animal handling features -- an integrated anesthesia system and temperature controlled stage and imaging chamber. Computer-controlled automation through a new, user-friendly interface provides easy zoom and focus adjustments and a rapid selection of a full range of excitation and emission filters. The Flex(TM) liquid crystal tunable filter (LCTF) provides fast, accurate spectral imaging from 500 to 950 nm, covering the full range of available in vivo fluorophores. The fully automated system allows easy instrument setup and calibration for faster, more accurate results within and between experiments. Maestro 2 provides increased sensitivity, automatic removal of autofluorescence for increase spectral contrast, and improved quantification of experimental results.

The Flex LCTF technology provides more accurate multiplexing capability and better quantification of experimental results. The software includes the Real Component Analysis(TM) (RCA) algorithm for automatic identification of spectral signatures and the Compute Spectra(TM) tool, which automatically separates combined or overlapping spectral signatures, enabling the end-user to build spectral libraries quickly and to rapidly analyze data. Quantitative measurement tools include component segmentation and regions of interest (ROI) analysis. Spatial, temporal and spectral separation of multiple signals are all enabled in the new Maestro 2, resulting in improved detection and quantification of co-localized signals in vivo.

"We are very excited about the Maestro 2 In Vivo Imaging System", says James Mansfield, Director of Multispectral Imaging Systems at CRi. "From its ergonomic design, optimized optics and user-friendly software tools, this system was designed and developed with the customers' needs in mind."

CRi, a Boston-based biomedical imaging company, has provided innovative optical imaging solutions for its customers for more than 20 years. A multidisciplinary team is dedicated to working with academic and commercial customers to provide high-value solutions. CRi provides comprehensive imaging and analysis solutions that enable the user to investigate and characterize biological phenotypes while preserving spatial context. With over 80 patents issued and pending, CRi's solution platforms encompass sub-cellular, cellular and whole animal applications. CRi's innovations are being utilized around the world to enable new breakthroughs in research, health and medicine. For more information visit our website at or contact:

David Daniels, Ph.D.

Director of Marketing


35-B Cabot Road, Woburn, MA 01801 USA

Tel: 1-781-935-9099, extension 149


SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):